

ORIGINAL RESEARCH

The Feasibility of Using Tri-Exponential Intra-Voxel Incoherent Motion DWI for Identifying the Microvascular Invasion in Hepatocellular Carcinoma

Yunfei Zhang^{1,2,*}, Ruofan Sheng^{1,2,*}, Chun Yang², Yongming Dai³, Mengsu Zeng^{1,2}

¹Shanghai Institute of Medical Imaging, Fudan University, Shanghai, 200032, People's Republic of China; ²Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, 200032, People's Republic of China; ³School of Biomedical Engineering, ShanghaiTech University, Shanghai, 200032, People's Republic of China

Correspondence: Yongming Dai, School of Biomedical Engineering, ShanghaiTech University, Shanghai, 200032, People's Republic of China, Tel +86 13917166155, Email daiyongming5555@163.com; Mengsu Zeng, Department of Radiology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, 200032, People's Republic of China, Tel +86-021-64041990, Email zengmengsu111@163.com

Purpose: To assess the effectiveness of tri-exponential Intra-Voxel Incoherent Motion (tri-IVIM) MRI in preoperatively identifying microvascular invasion (MVI) in hepatocellular carcinoma (HCC).

Patients and Methods: In this prospective study, 67 patients with HCC were included. Metrics from bi-exponential IVIM (bi-IVIM) and tri-IVIM were calculated. Subgroup comparisons were analyzed using the independent Student's *t*-test or Mann–Whitney *U*-test. Logistic regression was performed to explore clinical risk factors. Diagnostic performance was assessed using receiver operating characteristic (ROC) curves, calibration curves and decision curve analysis.

Results: MVI-positive HCCs exhibited significantly lower true diffusion coefficient (D_t) from bi-IVIM, as well as fast-diffusion coefficients (D_f) and slow-diffusion coefficients (D_s) from tri-IVIM, compared to MVI-negative HCCs (p < 0.05). Tumor size and alpha-fetoprotein (AFP) were identified as risk factors. The combination of tri-IVIM-derived metrics (D_s and D_f) yielded higher diagnostic accuracy (AUC = 0.808) compared to bi-IVIM (AUC = 0.741). A predictive model based on a nomogram was constructed using D_s , D_f , tumor size, and AFP, resulting in the highest diagnostic accuracy (AUC = 0.859). Decision curve analysis indicated that the constructed model, provided the highest net benefit by accurately stratifying the risk of MVI, followed by tri-IVIM and bi-IVIM. **Conclusion:** Tri-IVIM can provide information on perfusion and diffusion for evaluating MVI in HCC. Additionally, tri-IVIM outperformed bi-IVIM in identifying MVI-positive HCC. By integrating clinical risk factors and metrics from tri-IVIM, a predictive nomogram exhibited the highest diagnostic accuracy, potentially aiding in the noninvasive and preoperative assessment of MVI.

Keywords: tri-exponential intra-voxel incoherent motion, diffusion weighted imaging, hepatocellular carcinoma, microvascular invasion

Introduction

Hepatocellular carcinoma (HCC) ranks as the sixth most prevalent malignant tumor globally and is responsible for approximately 75–85% of all cases of primary liver cancer. It also stands as the second leading cause of cancer-related mortality.^{1,2} Numerous previous studies have provided compelling evidence for the significance of microvascular invasion (MVI) as a prognostic factor in HCC. Accurate identification of MVI can provide substantial clinical benefits by stratifying the risk of recurrence, predicting overall survival, and guiding clinical management.^{3–5} However, the current gold standard for evaluating MVI relies on histopathological examination, which has inherent limitations including invasiveness, time consumption, and the risk of sampling bias in liver tissue. Consequently, there is an urgent need for preoperative and noninvasive techniques to accurately identify MVI in HCC.

^{*}These authors contributed equally to this work

Diffusion-weighted imaging (DWI), which captures endogenous contrast derived from the diffusion characteristics of water molecules, has demonstrated considerable clinical utility in diagnostic imaging.^{6,7} Various intriguing DWI techniques have been developed and implemented in clinical imaging.^{8–17} Among these techniques, Intra-voxel incoherent motion (IVIM) MRI stands out as one of the most widely-used approaches. Since the introduction of IVIM theory in 1986. 18 over 1300 published studies have extensively showcased its clinical potential across a wide range of clinical scenarios (Data accessed from PubMed, May 2023). The core principle underlying IVIM is the existence of two diffusion components, namely perfusion and diffusion. In recent years, several researchers have proposed tri-exponential IVIM (tri-IVIM) as a potential alternative to the conventional bi-exponential IVIM (bi-IVIM), suggesting that the perfusion component should be further separated into two diffusion components: very fast diffusion and fast diffusion. 19,20 The unexpected confounding of these two components within a single perfusion component can compromise the accuracy and reliability of perfusion-related metrics derived from bi-IVIM. Evidence has shown that tri-IVIM provides better fitting accuracy than bi-IVIM for brain and liver applications. 20,21 However, most previous studies focused on feasibility investigations of tri-IVIM with small cohorts of healthy volunteers. To the best of our knowledge, there are few reports evaluating the value of tri-IVIM for abdominal malignancies.

The objective of this research is to assess the feasibility of tri-IVIM in characterizing HCC, specifically by exploring its potential for preoperative and noninvasive diagnosis of MVI-positive HCC, with a comparison to bi-IVIM.

Materials and Methods

Patients Cohort

This prospective study received approval from the local institutional review board, and written informed consent was obtained from all participating patients. This study also complies with the Declaration of Helsinki. Inclusion and exclusion criteria were applied as follows:

Inclusion Criteria: 1) Patients who were suspected of having primary liver cancers based on their medical history or other imaging examinations and had not undergone preoperative treatment. Exclusion Criteria: 1) Patients who were deemed ineligible for tumor resection or did not undergo surgery at our hospital. 2) Patients histopathologically diagnosed with malignancies other than HCC. 3) Patients with a time interval of three weeks or longer between the MRI examination and surgical resection. 4) Poor DWI image quality due to respiratory motion or other artifacts. 5) Absence of a histopathological report regarding the MVI status.

MRI Examination

All MRI examination of this research was performed with a 3T scanner (770, Shanghai UIH Healthcare Co, Ltd. Shanghai, China). Daily MRI sequences included an axial T2-weighted imaging sequence (repletion time (TR) = 2000.0 ms, echo time (TE) = 106.2 ms, field of view (FOV) = 380×380 mm², scanning matrix = 256×256 , section thickness = 6.0 mm, flip angle (FA) = 100°), an axial T1-weighted in- and opposed-phase imaging sequence (TR = 4.27 ms, TE = 1.24 ms, FOV = 300×400 mm², scanning matrix = 252×432, section thickness = 4 mm, FA = 10°), an axial contrastenhanced T1-weighted imaging sequence (TR = 3.28 ms, TE = 1.45 ms, FOV = 255×463 mm², scanning matrix = 237×480, FA = 10°). The tri-IVIM and bi-IVIM DWI were performed based on a single-shot echo-planar diffusionweighted MRI sequence (TR = 3800 ms, TE = 75.0 ms, FOV = 300×380 mm², scanning matrix = 202×256, section thickness = 6 mm, FA = 90° , b values = 0_1 , 20_1 , 40_1 , 50_1 , 100_1 , 200_1 , 500_1 , 800_3 and 1500_4 s/mm², the subscript indicates the number of averages).

Image Analysis

The post-processing of parametric maps for DWI was performed using a custom program script developed in-house and implemented on Python (Python 3.8; Python Software Foundation). Pixel-wise fitting of the tri-IVIM parametric maps was carried out with a dogleg algorithm and based on the following formula:

$$\frac{S_b}{S_0} = f_s \cdot \exp(-b \cdot D_s) + f_f \cdot \exp(-b \cdot D_f) + f_{vf} \cdot \exp(-b \cdot D_{vf})$$

$$f_s + f_f + f_{vf} = 1$$

Where S_b and S_0 represent the signal intensity of different b values and b = 0 s/mm², f_s and D_s represent the volume fraction of slow diffusion and slow diffusion coefficient. f_f and f_{vf} are the volume fractions of fast and very fast perfusion-related pseudo-diffusion. The D_f and D_{vf} are the diffusion coefficients of perfusion-related fast and very fast pseudo-diffusion

In addition to tri-IVIM, we also calculated the parametric maps of conventional bi-IVIM for comparison according to the following formula:

$$\frac{S_b}{S_0} = f_p \cdot \exp(-b \cdot D_p) + (1 - f_p) \cdot \exp(-b \cdot D_t)$$

Where S_b and S_0 represent the signal intensity of different b values and b = 0 s/mm², D_t represent the true diffusion coefficient. f_b is the volume fraction of perfusion-related pseudo-diffusion. The D_p is the pseudo-diffusion coefficient.

Two radiologists, RF. S and YF. Z, with 12 years and 8 years of experience in abdominal imaging, were enlisted to delineate the volumes of interest (VOIs) encompassing the entire HCC lesions on the DWI image with a b value of 500 s/mm². The final VOIs were determined through consensus between the two radiologists. In cases where consensus could not be reached, a third radiologist, MS. Z, with over 39 years of experience in abdominal imaging, was consulted for resolution. Subsequently, the VOIs were transferred to other parametric maps to calculate the mean values within the entire VOIs.

Statistical Analysis

The p values of larger than 0.05 given by the Shapiro–Wilk test suggest the quantitative data obey normal distribution. Significant differences in different DWI-derived metrics between the subgroups were explored by the independent Student's *t*-test (for normally-distributed data) or the Mann–Whitney *U*-test (for non-normally distributed data). Univariate and multivariate logistic regression was used for selecting the independent risk factors of MVI. The area under the receiver operative characteristics curve (AUC) was used for determining the diagnostic accuracy. Calibration curve analysis was conducted for validating the predictive accuracy. Power analysis was performed to estimate the required sample size by PASS software (version 2021, https://www.ncss.com/software/pass/). P values of less than or equal to 0.05 indicated significant differences. Except for power analysis, all other statistical analyses in this research were performed with R software (R version 4.1.0, R Foundation for Statistical Computing, Vienna, Austria).

Results

Patients Cohort

From 2020 to 2022, a total of 101 patients were initially enrolled in this prospective study. However, after applying the exclusion criteria (Figure 1), the following patients were excluded: 15 patients were not eligible for tumor resection or did not undergo surgery at our hospital, 5 patients had a time interval of three weeks or longer between the MRI examination and surgical resection, 4 patients were histopathologically diagnosed with malignancies other than HCC, 3 patients had poor DWI image quality and were not suitable for subsequent post-processing, and 7 patients lacked a histopathological diagnosis of MVI status. As a result, 67 patients were included in the final analysis (age: 57.6±10.4 years, 59 men, 8 women, 29 MVI-positive HCCs, and 38 MVI-negative HCCs). Detailed clinical characteristics can be found in Table 1. Representative MRI images of two patients, one with MVI and one without MVI, are displayed in Figure 2 and Figure 3, respectively.

Quantitative Comparison of DWI-Derived Metrics

The box-plots in Figure 4 show that significantly lower D_s , D_f and D_t were associated with the MVI (MVI-negative HCCs vs MVI-positive HCCs: $D_s = 1.17 \pm 0.22 \times 10^{-3}$ vs $0.96 \pm 0.23 \times 10^{-3}$ mm²/s, p < 0.001; $D_f = 34.85 \pm 17.22 \times 10^{-3}$ vs $20.93 \pm 7.78 \times 10^{-3}$ mm²/s, p < 0.001; $D_t = 1.23 \pm 0.23 \times 10^{-3}$ vs $1.02 \pm 0.24 \times 10^{-3}$ mm²/s, p = 0.001). Other metrics did not show the significant difference between the subgroups (MVI-negative HCCs vs MVI-positive HCCs: $f_p = 0.38 \pm 0.06$ vs 0.35 ± 0.06 , p = 0.060; $D_p = 0.060$; $D_p = 0.060$; D

Zhang et al Dovepress




Figure I The flowchart shows the inclusion and exclusion of subjects.

 $= 70.51 \pm 22.59 \times 10^{-3} \text{ vs } 67.90 \pm 26.46 \times 10^{-3} \text{ mm}^2/\text{s}, p = 0.909; D_{\text{vf}} = 1.50 \pm 0.25 \text{ vs } 1.52 \pm 0.33 \text{ mm}^2/\text{s}, p = 0.560; f_{\text{s}} = 0.60 \pm 0.07 \text{ vs } 0.59 \pm 0.10, p = 0.879; f_{\text{f}} = 0.11 \pm 0.08 \text{ vs } 0.11 \pm 0.07, p = 0.980; f_{\text{vf}} = 0.27 \pm 0.13 \text{ vs } 0.25 \pm 0.13, p = 0.511;).$

Evaluation of Diagnostic Accuracy

For individual metrics showing the significant differences between the subgroups, D_f (AUC = 0.767, specificity = 0.579, sensitivity = 0.897) has the best diagnostic performance followed by D_s (AUC = 0.760, specificity = 0.684, sensitivity = 0.793) and D_t (AUC = 0.741, specificity = 0.684, sensitivity = 0.793) (Figure 5). Taken D_f and D_s together by logistic

Table I Clinical Characteristics

Hepatitis B virus Hepatitis C virus α-fetoprotein ≥ 20 ng/mL < 20 ng/mL < 20 ng/mL	Characteristics	No of Patient (n = 67)	
Female 8 (11.9%) Age (y) 57.6±10.4 (Min: 33.0, Max: 83.0) Etiology of liver disease 67 (100.0%) Hepatitis C virus 3 (4.5%) u-fetoprotein 2 20 ng/mL ∠ 20 ng/mL 41 (61.2%) ∠ 20 ng/mL 26 (38.8%) Tumor Size (cm) 4.87±3.27 (Min: 1.0, Max: 15.0) Degree of Differentiation 47 (70.1%) Well and medium 47 (70.1%) Poor 20 (29.9%) Fibrosis 33 (49.3%) With Without 34 (50.7%) Total bilirubin (TBiL) 9 (13.4%) ≤ 20.4 μmol/L 9 (13.4%) ≤ 8 (86.6%) 58 (86.6%) Direct Bilirubin (DBiL) 58 (86.6%) ≥6.8 μmol/L 58 (86.6%) Alanine Aminotransferase (ALT) 58 (86.6%) ≥35 U/L 51 (76.1%) Aspartate Aminotransferase (AST) 240 U/L ≤40 U/L 55 (82.1%) γ-glutamyl transferase (γGT) 22 (32.8%) ≥6 0 U/L 45 (67.2%) Carcinoembryonic Antigen (CEA) 25 ng/mL	Gender		
57.6±10.4 (Min: 33.0, Max: 83.0) Etiology of liver disease Hepatitis B virus Hepatitis C virus a. (100.0%) 4 (100.0%) 3 (4.5%) a. (100.0%) 4 (100.0%) 3 (4.5%) a. (100.0%) 4 (100.0%) <td>Male</td> <td colspan="2">59 (88.1%)</td>	Male	59 (88.1%)	
Hepatitis B virus Hepatitis C virus α-fetoprotein ≥ 20 ng/mL < 20 ng/mL < 20 ng/mL	Female	8 (11.9%)	
Hepatitis B virus Hepatitis C virus α-fetoprotein ≥ 20 ng/mL < 20 ng/mL	Age (y)	57.6±10.4 (Min: 33.0, Max: 83.0)	
Hepatitis C virus α-fetoprotein ≥ 20 ng/mL < 20 ng/mL 20 (38.8%) Tumor Size (cm) Degree of Differentiation Well and medium Poor Fibrosis With Without Total bilirubin (TBiL) >20.4 μmol/L ≥0.8 μmol/L >6.8 μmol/L Alanine Aminotransferase (ALT) >35 U/L ≤35 U/L Δ49 U/L γ-glutamyl transferase (γGT) >60 U/L ≤5 ng/mL <5 ng/mL ≤5 ng/mL ≤5 ng/mL ≤5 ng/mL ⟨57 ng/mL Carbohydrate Antigen 19–9 (CA199) ≥37 ng/mL MVI-Positive 41 (61.2%) 41 (61.2%) 42 (63.8%) 41 (61.2%) 42 (38.8%) 41 (61.2%) 42 (38.8%) 47 (70.1%) 48 (70.1%) 49 (13.4%) 58 (86.6%) 9 (13.4%) 58 (86.6%) 16 (23.9%) 51 (76.1%) 52 (32.8%) 45 (67.2%) Carcinoembryonic Antigen (CEA) ≥5 ng/mL ⟨5 ng/mL ⟨5 ng/mL ⟨5 ng/mL ⟨6 (9.0%) 61 (91.0%) MVI MVI-Positive	Etiology of liver disease		
α-fetoprotein ≥ 20 ng/mL 41 (61.2%) 26 (38.8%) Tumor Size (cm) 4.87±3.27 (Min: 1.0, Max: 15.0) Degree of Differentiation 47 (70.1%) 20 (29.9%) Fibrosis With 33 (49.3%) 34 (50.7%) Without 34 (50.7%) 34 (50.7%) Total bilirubin (TBiL) 9 (13.4%) 220.4 μmol/L 58 (86.6%) ≥20.4 μmol/L 9 (13.4%) 26.8 μmol/S 28 (86.6%) Direct Bilirubin (DBiL) 9 (13.4%) 26.8 (86.6%) ≥6.8 μmol/L 9 (13.4%) 28 (86.6%) Alanine Aminotransferase (ALT) 28 (86.6%) ≥35 U/L 16 (23.9%) 51 (76.1%) Aspartate Aminotransferase (AST) 12 (17.9%) 58 (82.1%) γ-glutamyl transferase (γGT) 22 (32.8%) 45 (67.2%) Carcinoembryonic Antigen (CEA) 25 ng/mL 8 (11.9%) 59 (88.1%) Carbohydrate Antigen 19–9 (CA199) 237 ng/mL 6 (9.0%) 61 (91.0%) MVI MVI-Positive 29 (43.3%)	Hepatitis B virus	67 (100.0%)	
2 0 ng/mL	Hepatitis C virus	3 (4.5%)	
< 20 ng/mL	lpha-fetoprotein		
Tumor Size (cm) Degree of Differentiation Well and medium Poor Fibrosis With Without Total bilirubin (TBiL) >20.4 μmol/L ≤20.4 μmol/L 58 (86.6%) Direct Bilirubin (DBiL) >6.8 μmol/ ≤6.8 μmol/L Alanine Aminotransferase (ALT) >35 U/L ≤35 U/L Aspartate Aminotransferase (AST) >40 U/L √-glutamyl transferase (γGT) >60 U/L ≤60 U/L Carcinoembryonic Antigen (CEA) ≥37 ng/mL (37 ng/mL MVI MVI-Positive 47 (70.1%) 47 (70.1%) 20 (29.9%) 47 (70.1%) 48 (13.4%) 58 (86.6%) 9 (13.4%) 58 (86.6%) 9 (13.4%) 58 (86.6%) 16 (23.9%) 58 (86.6%) 12 (17.9%) 55 (82.1%) 7-glutamyl transferase (γGT) 59 (88.1%) 6 (9.0%) 6 (9.0%) 6 (9.0%) 6 (9.0%) MVI MVI-Positive	≥ 20 ng/mL	41 (61.2%)	
Degree of Differentiation Well and medium 47 (70.1%) Poor 20 (29.9%) Fibrosis With 33 (49.3%) Without 34 (50.7%) Total bilirubin (TBiL) >20.4 μmol/L 9 (13.4%) ≤20.4 μmol/L 58 (86.6%) Direct Bilirubin (DBiL) >6.8 μmol/ 9 (13.4%) ≤6.8 μmol/L 58 (86.6%) Alanine Aminotransferase (ALT) >35 U/L 16 (23.9%) ≤35 U/L 16 (23.9%) Aspartate Aminotransferase (AST) >40 U/L >40 U/L 12 (17.9%) ≤40 U/L 55 (82.1%) γ-glutamyl transferase (γGT) >60 U/L ≤60 U/L 22 (32.8%) <60 U/L	< 20 ng/mL	26 (38.8%)	
Well and medium 47 (70.1%) Poor 20 (29.9%) Fibrosis With 33 (49.3%) Without 34 (50.7%) Total bilirubin (TBiL) >20.4 μmol/L 9 (13.4%) ≤20.4 μmol/L 58 (86.6%) Direct Bilirubin (DBiL) >6.8 μmol/L 9 (13.4%) ≤6.8 μmol/L 58 (86.6%) Alanine Aminotransferase (ALT) >35 U/L 16 (23.9%) ≤35 U/L 51 (76.1%) Aspartate Aminotransferase (AST) >40 U/L 12 (17.9%) ≤40 U/L 55 (82.1%) γ-glutamyl transferase (γGT) 22 (32.8%) ≤60 U/L 22 (32.8%) <60 U/L	Tumor Size (cm)	4.87±3.27 (Min: 1.0, Max: 15.0)	
Fibrosis 33 (49.3%) With 34 (50.7%) Total bilirubin (TBiL) 9 (13.4%) ≥20.4 μmol/L 9 (13.4%) ≤20.4 μmol/L 58 (86.6%) Direct Bilirubin (DBiL) 9 (13.4%) ≤6.8 μmol/L 58 (86.6%) Alanine Aminotransferase (ALT) 16 (23.9%) ≤35 U/L 51 (76.1%) Aspartate Aminotransferase (AST) 12 (17.9%) ≤40 U/L 12 (17.9%) ≤40 U/L 55 (82.1%) γ-glutamyl transferase (γGT) 20 (32.8%) ≤60 U/L 22 (32.8%) ≤60 U/L 45 (67.2%) Carcinoembryonic Antigen (CEA) 8 (11.9%) ≤5 ng/mL 59 (88.1%) Carbohydrate Antigen 19-9 (CA199) 237 ng/mL ≤37 ng/mL 61 (91.0%) MVI MVI-Positive 29 (43.3%)	Degree of Differentiation		
Fibrosis With Without Total bilirubin (TBiL) >20.4 μmol/L ≤20.4 μmol/L S8 (86.6%) Direct Bilirubin (DBiL) >6.8 μmol/ ≤6.8 μmol/L Alanine Aminotransferase (ALT) >35 U/L ≤35 U/L Aspartate Aminotransferase (AST) >40 U/L ≤40 U/L γ-glutamyl transferase (γGT) >60 U/L ≤60 U/L Carcinoembryonic Antigen (CEA) ≥5 ng/mL <5 ng/mL Carbohydrate Antigen 19–9 (CA199) ≥37 ng/mL MVI MVI-Positive 9 (13.4%) 9 (13.4%) 58 (86.6%) 16 (23.9%) 51 (76.1%) 58 (86.6%) 16 (23.9%) 58 (86.6%) 16 (23.9%) 59 (82.1%) 59 (82.1%) 9 (13.4%) 58 (86.6%) 16 (23.9%) 58 (86.6%) 16 (23.9%) 59 (82.1%) 59 (82.1%) 60 U/L 60 U/L 61 (91.0%) MVI MVI-Positive	Well and medium	47 (70.1%)	
With 33 (49.3%) Without 34 (50.7%) Total bilirubin (TBiL) 9 (13.4%) ≥20.4 μmol/L 58 (86.6%) Direct Bilirubin (DBiL) 9 (13.4%) ≥6.8 μmol/L 58 (86.6%) Alanine Aminotransferase (ALT) >35 U/L ≥35 U/L 16 (23.9%) ≤35 U/L 51 (76.1%) Aspartate Aminotransferase (AST) >40 U/L ≤40 U/L 12 (17.9%) ≤40 U/L 55 (82.1%) γ-glutamyl transferase (γGT) 22 (32.8%) ≤60 U/L 22 (32.8%) ≤60 U/L 45 (67.2%) Carcinoembryonic Antigen (CEA) 8 (11.9%) ≥5 ng/mL 8 (11.9%) <5 ng/mL	Poor	20 (29.9%)	
Without Total bilirubin (TBiL) >20.4 μmol/L 9 (13.4%) ≤20.4 μmol/L 58 (86.6%) Direct Bilirubin (DBiL) >6.8 μmol/L 9 (13.4%) ≤6.8 μmol/L 58 (86.6%) Alanine Aminotransferase (ALT) >35 U/L 16 (23.9%) ≤35 U/L 51 (76.1%) Aspartate Aminotransferase (AST) >40 U/L 12 (17.9%) ≤40 U/L 55 (82.1%) γ-glutamyl transferase (γGT) 22 (32.8%) ≤60 U/L 22 (32.8%) ≤60 U/L 45 (67.2%) Carcinoembryonic Antigen (CEA) ≥5 ng/mL 8 (11.9%) <5 ng/mL	Fibrosis		
Total bilirubin (TBiL) >20.4 μmol/L 9 (13.4%) ≤20.4 μmol/L 58 (86.6%) Direct Bilirubin (DBiL) 9 (13.4%) ≤6.8 μmol/L 58 (86.6%) Alanine Aminotransferase (ALT) 16 (23.9%) ≤35 U/L 16 (23.9%) ≤35 U/L 51 (76.1%) Aspartate Aminotransferase (AST) 12 (17.9%) ≤40 U/L 55 (82.1%) γ-glutamyl transferase (γGT) 22 (32.8%) ≤60 U/L 22 (32.8%) ≤60 U/L 45 (67.2%) Carcinoembryonic Antigen (CEA) 8 (11.9%) ≤5 ng/mL 59 (88.1%) Carbohydrate Antigen 19–9 (CA199) ≥37 ng/mL 6 (9.0%) <37 ng/mL	With	33 (49.3%)	
>20.4 μmol/L ≤20.4 μmol/L Direct Bilirubin (DBiL) >6.8 μmol/L Alanine Aminotransferase (ALT) >35 U/L ≤35 U/L Aspartate Aminotransferase (AST) >40 U/L ≤40 U/L γ-glutamyl transferase (γGT) >60 U/L ≤60 U/L Carcinoembryonic Antigen (CEA) ≥5 ng/mL <5 ng/mL Carbohydrate Antigen 19–9 (CA199) ≥37 ng/mL MVI MVI-Positive 9 (13.4%) 58 (86.6%) 9 (13.4%) 58 (86.6%) 9 (13.4%) 58 (86.6%) 9 (13.4%) 58 (86.6%) 9 (13.4%) 58 (86.6%) 9 (13.4%) 58 (86.6%) 16 (23.9%) 58 (86.6%) 16 (23.9%) 51 (76.1%) 52 (82.1%) 53 (82.1%) 54 (67.2%) 55 (82.1%) 57 (87.2%) 66 (9.0%) 61 (91.0%) MVI MVI-Positive	Without	34 (50.7%)	
≤20.4 μmol/L 58 (86.6%) Direct Bilirubin (DBiL) 9 (13.4%) ≤6.8 μmol/L 58 (86.6%) Alanine Aminotransferase (ALT) 16 (23.9%) ≤35 U/L 51 (76.1%) Aspartate Aminotransferase (AST) >40 U/L 12 (17.9%) ≤40 U/L 55 (82.1%) γ-glutamyl transferase (γGT) 22 (32.8%) ≤60 U/L 45 (67.2%) Carcinoembryonic Antigen (CEA) 25 ng/mL 8 (11.9%) ≤5 ng/mL 59 (88.1%) Carbohydrate Antigen 19–9 (CA199) ≥37 ng/mL 6 (9.0%) <37 ng/mL 61 (91.0%) MVI MVI-Positive 29 (43.3%)	Total bilirubin (TBiL)		
Direct Bilirubin (DBiL) >6.8 μmol/ 9 (13.4%) ≤6.8 μmol/L 58 (86.6%) Alanine Aminotransferase (ALT) >35 U/L 16 (23.9%) ≤35 U/L 51 (76.1%) Aspartate Aminotransferase (AST) >40 U/L 12 (17.9%) ≤40 U/L 55 (82.1%) γ-glutamyl transferase (γGT) 22 (32.8%) ≤60 U/L 22 (32.8%) ≤60 U/L 45 (67.2%) Carcinoembryonic Antigen (CEA) 8 (11.9%) ≤5 ng/mL 59 (88.1%) Carbohydrate Antigen 19-9 (CA199) ≥37 ng/mL 6 (9.0%) <37 ng/mL	>20.4 μmol/L	9 (13.4%)	
>6.8 μmol/ ≤6.8 μmol/L Alanine Aminotransferase (ALT) >35 U/L ≤35 U/L Aspartate Aminotransferase (AST) >40 U/L ≤40 U/L γ-glutamyl transferase (γGT) >60 U/L ≤60 U/L Carcinoembryonic Antigen (CEA) ≥5 ng/mL <5 ng/mL Carbohydrate Antigen 19–9 (CA199) ≥37 ng/mL MVI MVI-Positive 58 (86.6%) 16 (23.9%) 51 (76.1%) 52 (17.9%) 52 (82.1%) 7-2 (17.9%) 52 (32.8%) 45 (67.2%) 8 (11.9%) 59 (88.1%) 6 (9.0%) 61 (91.0%) MVI MVI-Positive	≤20.4 μmol/L	58 (86.6%)	
≤6.8 μmol/L Alanine Aminotransferase (ALT) >35 U/L ≤35 U/L Aspartate Aminotransferase (AST) >40 U/L ≤40 U/L γ-glutamyl transferase (γGT) >60 U/L ≤60 U/L 22 (32.8%) ≤60 U/L Carcinoembryonic Antigen (CEA) ≥5 ng/mL <5 ng/mL <5 ng/mL Carbohydrate Antigen 19–9 (CA199) ≥37 ng/mL ⟨37 ng/mL MVI MVI-Positive 58 (86.6%) 16 (23.9%) 51 (76.1%) 52 (17.9%) 52 (82.1%) 22 (32.8%) 45 (67.2%) 6 (9.0%) 6 (9.0%) 6 (9.0%) 6 (9.0%) 6 (9.0%) 9 (43.3%)	Direct Bilirubin (DBiL)		
Alanine Aminotransferase (ALT) >35 U/L 16 (23.9%) ≤35 U/L 51 (76.1%) Aspartate Aminotransferase (AST) >40 U/L 12 (17.9%) ≤40 U/L 55 (82.1%) γ-glutamyl transferase (γGT) 22 (32.8%) ≤60 U/L 45 (67.2%) Carcinoembryonic Antigen (CEA) 8 (11.9%) ≤5 ng/mL 8 (11.9%) <5 ng/mL	>6.8 μmol/	9 (13.4%)	
>35 U/L ≤35 U/L Aspartate Aminotransferase (AST) >40 U/L ≤40 U/L 7-glutamyl transferase (γGT) >60 U/L ≤60 U/L Carcinoembryonic Antigen (CEA) ≥5 ng/mL <5 ng/mL Carbohydrate Antigen 19–9 (CA199) ≥37 ng/mL ⟨37 ng/mL MVI MVI-Positive 16 (23.9%) 51 (76.1%) 12 (17.9%) 55 (82.1%) 72 (32.8%) 45 (67.2%) 8 (11.9%) 59 (88.1%) 6 (9.0%) 61 (91.0%) MVI MVI-Positive 29 (43.3%)	≤6.8 μmol/L	58 (86.6%)	
≤35 U/L Aspartate Aminotransferase (AST) >40 U/L ≤40 U/L γ-glutamyl transferase (γGT) >60 U/L ≤60 U/L Carcinoembryonic Antigen (CEA) ≥5 ng/mL <5 ng/mL <5 ng/mL Carbohydrate Antigen 19–9 (CA199) ≥37 ng/mL ⟨37 ng/mL MVI MVI-Positive 51 (76.1%) 52 (76.1%) 53 (82.1%) 22 (32.8%) 45 (67.2%) 8 (11.9%) 59 (88.1%) 6 (9.0%) 61 (91.0%) MVI MVI-Positive	Alanine Aminotransferase (ALT)		
Aspartate Aminotransferase (AST) >40 U/L ≤40 U/L 55 (82.1%) γ-glutamyl transferase (γGT) >60 U/L ≤60 U/L Carcinoembryonic Antigen (CEA) ≥5 ng/mL <5 ng/mL 59 (88.1%) Carbohydrate Antigen 19–9 (CA199) ≥37 ng/mL 61 (91.0%) MVI MVI-Positive 12 (17.9%) 55 (82.1%) 22 (32.8%) 45 (67.2%) 8 (11.9%) 59 (88.1%) 6 (9.0%) 61 (91.0%)	>35 U/L	16 (23.9%)	
>40 U/L ≤40 U/L 55 (82.1%) γ-glutamyl transferase (γGT) >60 U/L 22 (32.8%) ≤60 U/L 45 (67.2%) Carcinoembryonic Antigen (CEA) ≥5 ng/mL <5 ng/mL 59 (88.1%) Carbohydrate Antigen 19–9 (CA199) ≥37 ng/mL 6 (9.0%) <37 ng/mL MVI MVI-Positive 29 (43.3%)	≤35 U/L	51 (76.1%)	
≤40 U/L γ-glutamyl transferase (γGT) >60 U/L ≤60 U/L Carcinoembryonic Antigen (CEA) ≥5 ng/mL <5 ng/mL 59 (82.1%) 22 (32.8%) 45 (67.2%) 8 (11.9%) 59 (88.1%) Carbohydrate Antigen 19–9 (CA199) ≥37 ng/mL 60 (9.0%) 61 (91.0%) MVI MVI-Positive 29 (43.3%)	Aspartate Aminotransferase (AST)		
γ-glutamyl transferase (γGT) >60 U/L ≤60 U/L 45 (67.2%) Carcinoembryonic Antigen (CEA) ≥5 ng/mL <5 ng/mL 59 (88.1%) Carbohydrate Antigen 19–9 (CA199) ≥37 ng/mL ⟨37 ng/mL MVI MVI-Positive 29 (43.3%)	>40 U/L	12 (17.9%)	
>60 U/L ≤60 U/L 60 U/L Carcinoembryonic Antigen (CEA) ≥5 ng/mL <5 ng/mL 70 (Sarbohydrate Antigen 19–9 (CA199) ≥37 ng/mL 60 (9.0%) 61 (91.0%) MVI MVI-Positive 22 (32.8%) 45 (67.2%) 8 (11.9%) 59 (88.1%) 6 (9.0%) 6 (9.0%) 6 (9.0%) 6 (91.0%) 9 (43.3%)	≤40 U/L	55 (82.1%)	
≤60 U/L Carcinoembryonic Antigen (CEA) ≥5 ng/mL <5 ng/mL 59 (88.1%) Carbohydrate Antigen 19–9 (CA199) ≥37 ng/mL <37 ng/mL MVI MVI-Positive 45 (67.2%) 8 (11.9%) 59 (88.1%) 6 (9.0%) 6 (9.0%) 61 (91.0%) 29 (43.3%)	γ -glutamyl transferase (γ GT)		
Carcinoembryonic Antigen (CEA) 8 (11.9%) ≥5 ng/mL 59 (88.1%) Carbohydrate Antigen 19–9 (CA199) ≥37 ng/mL 6 (9.0%) ≤37 ng/mL 61 (91.0%) MVI MVI-Positive 29 (43.3%)	>60 U/L	22 (32.8%)	
≥5 ng/mL 8 (11.9%) <5 ng/mL 59 (88.1%) Carbohydrate Antigen 19–9 (CA199) ≥37 ng/mL 6 (9.0%) <37 ng/mL 61 (91.0%) MVI MVI-Positive 29 (43.3%)	≤60 U/L	45 (67.2%)	
	Carcinoembryonic Antigen (CEA)		
Carbohydrate Antigen 19–9 (CA199) 6 (9.0%) ≥37 ng/mL 61 (91.0%) MVI 61 (91.3%)	≥5 ng/mL	8 (11.9%)	
≥37 ng/mL 6 (9.0%) <37 ng/mL 61 (91.0%) MVI MVI-Positive 29 (43.3%)	<5 ng/mL	59 (88.1%)	
<37 ng/mL 61 (91.0%) MVI MVI-Positive 29 (43.3%)	Carbohydrate Antigen 19-9 (CA199)		
MVI-Positive 29 (43.3%)	≥37 ng/mL	6 (9.0%)	
MVI-Positive 29 (43.3%)	<37 ng/mL	61 (91.0%)	
	MVI		
MVI-Negative 38 (56.7%)	MVI-Positive	29 (43.3%)	
	MVI-Negative	38 (56.7%)	

regression, the tri-IVIM-based model resulted in improved diagnostic accuracy (AUC = 0.808, specificity = 0.658, sensitivity = 0.862) (Figure 5).

According to the multivariate logistic regression (Table 2), tumor size (odds ratio (OR) = 1.248, 95% CI of OR = 1.020-1.527, p = 0.032) and alpha-fetoprotein (AFP) (OR = 3.653, 95% CI of OR = 1.174-11.371, p = 0.025) were selected as independent risk factors of MVI. A nomogram-based predictor was constructed with tumor size, AFP, D_s and D_f (Figure 6A), showing the best diagnostic accuracy (AUC = 0.859, Specificity = 0.842, Sensitivity = 0.793, Figure 6B). D_t was excluded from the model construction because it provided similar information related to cellularity as D_s , and its diagnostic performance was not superior to that of D_s . The calibration curves in Figure 6C indicate a strong agreement




Figure 2 Representative MRI images including the T2WI, TIWI, DWI of $b = 100 \text{ s/mm}^2$ and bi-IVIM-derived parametric maps $(f_p, D_t \text{ and } D_p)$ as well as tri-IVIM-derived parametric maps $(f_p, D_t \text{ and } D_p)$ of a patient with MVI-negative HCC.

Notes: It is important to note that the parametric pseudo-color maps of the segmented tumors were superimposed on the DWI images with a b-value of 500 s/mm². All pseudo-color maps utilize the same color bar, which ranges from blue to red. The following ranges apply to different parameters: f_p , f_s and f_{vf} range from 0.0 to 1.0; D_t and D_s range from 0.0 to 5×10^{-3} mm²/s; D_p and D_f range from 0.0 to 200×10^{-3} mm²/s; D_{vf} ranges from 0.0 to $10,000\times10^{-3}$ mm²/s.

between the predicted risk of MVI generated by the nomogram model and the actual risk of MVI. This demonstrates the reliability and accuracy of the nomogram in assessing MVI. The decision curve analysis also demonstrated that with the highest predictive accuracy, the nomogram-based model can yield the highest net benefit by accurately stratifying the risk of MVI compared to other metrics (Figure 7).

Power Analysis and Sample Size Estimation

The required sample size for this study was estimated at the beginning using power analysis.

As this study is centered on diagnostic evaluation, and the ROC analysis is an important statistical analysis for determining the diagnostic accuracy for this research. Therefore, we conducted a power analysis specifically tailored to the ROC analysis employed in this study. Different effect values (AUCs) were considered with a significance level of 0.05 and a statistical power of 0.85. The results showed that the minimum required sample sizes for AUCs of 0.60, 0.65, 0.70, 0.75, 0.80, 0.85, and 0.90 were 296, 128, 70, 44, 30, 20, and 14, respectively. In this study, we included a total of 67 subjects, and the observed AUCs for the metrics showing significant differences between the subgroups and the constructed models ranged from 0.741 to 0.859. In accordance with the principles of power analysis, it is important to note that, when considering a specific statistical power and significance level, the required sample size exhibits a negative




Figure 3 Representative MRI images including the T2WI, T1WI, DWI of $b = 100 \text{ s/mm}^2$ and bi-IVIM-derived parametric maps $(f_p, D_t \text{ and } D_p)$ as well as tri-IVIM-derived parametric maps $(f_s, f_t, f_{v_t}, D_s, D_t \text{ and } D_{v_t})$ of a patient with MVI-positive HCC.

Note: The color bar and ranges of different metrics are same as those in Figure 2.

correlation with effect values. These findings indicate that the sample size in this study ensures a relatively high statistical power (0.85) for the evaluation of diagnostic accuracy.

Discussion

This study represents a preliminary evaluation of the value of tri-IVIM for assessing MVI in HCC. To the best of our knowledge, there have been few attempts made to explore the clinical utility of tri-IVIM in abdominal malignancies. Our findings demonstrate that tri-IVIM can serve as a noninvasive approach for preoperative identification of MVI-positive HCC. Specifically, we observed significant differences in two metrics derived from tri-IVIM (D_f and D_s), whereas only one metric derived from bi-IVIM (D_t) showed a significant difference between MVI-positive and MVI-negative HCCs. Moreover, the combination of D_f and D_s , which respectively reflect perfusion and diffusion, resulted in superior diagnostic performance compared to bi-IVIM. The results presented above indicate that tri-IVIM analysis offers more valuable markers for assessing MVI from diverse biological perspectives. We identified two clinical factors, tumor size, and AFP, as independent risk factors for MVI. By integrating these clinical factors with tri-IVIM-derived metrics, we constructed a predictive model that displayed the highest diagnostic accuracy for MVI. This approach may provide new insights for the preoperative, noninvasive, and accurate diagnosis of MVI-positive HCC.

Our findings revealed that the presence of MVI was associated with significantly lower D_f , D_s , and D_t . However, other metrics derived from bi-IVIM or tri-IVIM did not show significant differences between the two groups. The potential biophysical explanations for these findings can be speculated as follows: 1) D_s and D_t have similar biological

Zhang et al Dovepress




Figure 4 Quantitative comparison of bi-IVIM and tri-IVIM derived metrics between MVI-negative and MVI-positive HCCs.

insights. Both metrics quantify true diffusion and reflect tissue cellularity. Previous research has demonstrated that the presence of MVI indicates a higher degree of malignancy with increased tumor cell proliferation and a higher nucleocytoplasmic ratio, which results in a reduction in the extracellular space. As a consequence, the diffusion of water molecules becomes more restricted, leading to significantly lower diffusion coefficients in MVI-positive HCC. Our findings are consistent with previous publications that have identified significantly lower diffusion coefficients as indicators of MVI-positive HCC.^{22–24}

2) D_f , on the other hand, reflects perfusion-related diffusion. While exuberant neovascularization is essential to meet the demands of oxygen and nutrient supply during hepatocarcinogenesis, these neovascular vessels are often characterized by vascular leakage and defective vascular remodeling.²⁵ Therefore, the decreased D_f observed in MVI-positive HCC may be associated with these vascular abnormalities.

Many investigators have utilized IVIM for diagnosing MVI-positive HCC. In these studies, it was found that only IVIM-derived D_t showed statistical significance, while D_p and f exhibited high variance and did not demonstrate statistical differences, consistent with our findings. ^{22,23,26,27} The liver exhibits distinctive histological features, encompassing various types of vessels such as arteries/arterioles, portal veins/venules, and hepatic veins/venules. In addition, it contains sinusoid capillaries, bile ducts, and an extensive lymphatic system. Within these compartments, there are




Figure 5 The receiver characteristics curves (ROC) of D_f , D_s , D_t and the combination of D_f and D_s ($D_f + D_s$).

flowing or moving spins that are intricately interconnected either directly or indirectly. This intricate network of vessels and structures contributes to the presence of an extra diffusion component in the liver. Recent evidence suggests the existence of a third diffusion compartment in the liver characterized by very fast diffusion.^{28–31} The confounding of two

Table 2 Explore the Independent Risk Factors of MVI Through Univariable and Multivariable Logistic Regression Analysis

Parameters	Univariable Analysis		Multivariable Analysis	
	OR (95% CI)	Р	OR (95% CI)	Р
Gender	0.411 (0.090–1.886)	0.253		0.523
CEA	0.968 (0.923-1.016)	0.187		0.738
CA199	2.217 (0.563–8.738)	0.255		0.209
HCV	0.643 (0.055–7.455)	0.724		0.646
Tumor Size	1.268 (1.050-1.531)	0.013	1.248 (1.020–1.527)	0.032
TBIL	0.615 (0.140–2.702)	0.520		0.850
DBIL	0.328 (0.063-1.715)	0.187		0.654
ALT	1.429 (0.463-4.411)	0.535		0.788
AST	1.391 (0.398-4.866)	0.605		0.472
γGT	1.500 (0.537-4.188)	0.439		0.780
AFP	4.259 (1.416–12.812)	0.010	3.653 (1.174–11.371)	0.025

Abbreviations: CEA, carcinoembryonic antigen; CA199, Carbohydrate antigen199; HCV, Hepatitis C; TBIL, total bilirubin; DBIL, direct bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; γ GT, γ glutamyltransferase; AFP, alpha-fetoprotein.




Figure 6 Evaluation of the nomogram-based model.

Notes: (A) The nomogram plot. (B) The ROC and (C) calibration curve of the constructed nomogram model.

diffusion components, fast diffusion and very fast pseudo-diffusion, within a single perfusion component, is likely the main factor contributing to high variance and suboptimal diagnostic performance of the bi-IVIM derived parameters D_p and $f.^{28}$ According to the tri-IVIM theory, D_{vf} represents the component of very fast diffusion, which can arise from the complex interactions of spins within various tissue types, including arteries/arterioles, portal veins/venules, hepatic veins/venules, sinusoid capillaries, bile ducts, and the extensive lymphatic system. However, due to the intricate nature of these interactions, D_{vf} may exhibit high variance and limited diagnostic power. Additionally, the volume fractions of the different diffusion components were not found to have significant differences, suggesting that these volume fractions are not sensitive enough to differentiate between MVI-positive HCC and MVI-negative HCC.

Among all individual metrics from tri-IVIM and bi-IVIM, D_f demonstrated the best performance for diagnosing MVI-positive HCC, followed by D_s and D_t . Combining the tri-IVIM-derived D_s and D_f resulted in a significantly higher AUC, indicating that tri-IVIM is more powerful in identifying MVI compared to IVIM, which relies on a single metric of D_t as the diagnostic marker. These results highlight the superior capability of tri-IVIM in the preoperative evaluation of MVI with high accuracy. Additionally, by separating the fast diffusion component and very fast diffusion component, the perfusion-related metric can serve as a diagnostic marker and exhibit excellent diagnostic performance. Our study also found that increased tumor size and elevated AFP levels were both risk factors for MVI. Based on these findings, we constructed a nomogram-based predictive model that incorporates D_s , D_f , tumor size, and AFP. The predictive model exhibited a strong diagnostic power, as indicated by an AUC of 0.859. This suggests that the model has the potential to serve as a valuable and cost-effective tool for assisting in the noninvasive and preoperative identification of MVI-positive HCC.




Figure 7 The decision curve of the nomogram-based model, tri-IVIM (D_s+D_f) and bi-IVIM (D_t) .

This study is subject to several limitations. Firstly, the sample size of this prospective study was not very large, highlighting the need for larger sample sizes and external validation to strengthen the evidence. Secondly, the exact biological origin of the component with very fast diffusion in tri-IVIM remains unclear and requires further exploration. Therefore, more research is needed to elucidate the detailed mechanisms underlying the correlation between D_{vf} and MVI. Thirdly, it is important to note that MVI can be graded into different grades, such as M0, M1, and M2. However, this proof-of-concept study focused solely on evaluating the feasibility of using tri-IVIM for diagnosing MVI-positive HCC, rather than grading the extent of MVI.

Conclusion

Our findings highlight the feasibility and value of tri-IVIM in identifying MVI in HCC. Specifically, both the perfusion-related $D_{\rm f}$ and diffusion-related $D_{\rm s}$ obtained from tri-IVIM proved to be valuable indicators for MVI. Furthermore, tri-IVIM demonstrated superior diagnostic accuracy compared to bi-IVIM. Ultimately, the construction of a predictive nomogram that combines both clinical factors and tri-IVIM resulted in the highest accuracy for diagnosing MVI-positive HCC. These findings signified that tri-IVIM has the potential for enhancing prognostic prediction and guiding clinical management in the context of MVI-positive HCC.

Acknowledgments

We thank Home for Researchers team for language editing assistance.

Disclosure

The authors report no conflicts of interest in this work.

References

- 1. Llovet JM, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma. *Nat Rev Clin Oncol*. 2022;19(3):151–172. doi:10.1038/s41571-021-00573-2
- Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660

Zhang et al Dovepress

3. Rodriguez-Peralvarez M, Luong TV, Andreana L, Meyer T, Dhillon AP, Burroughs AK. A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability. *Ann Surg Oncol.* 2013;20(1):325–339. doi:10.1245/s10434-012-2513-1

- 4. Zhang E-L, Cheng Q, Huang Z-Y, Dong W. Revisiting surgical strategies for hepatocellular carcinoma with microvascular invasion. *Front Oncol.* 2021;11:691354. doi:10.3389/fonc.2021.691354
- 5. Zheng Z, Guan R, Jianxi W, et al. Microvascular invasion in hepatocellular carcinoma: a review of its definition, clinical significance, and comprehensive management. *J Oncol.* 2022;2022:1–10. doi:10.1155/2022/9567041
- Mannelli L, Nougaret S, Vargas HA, Do RK. Advances in diffusion-weighted imaging. Radiologic Clinics. 2015;53(3):569–581. doi:10.1016/j. rcl.2015.01.002
- 7. Bammer R. Basic principles of diffusion-weighted imaging. Eur J Radiol. 2003;45(3):169–184. doi:10.1016/S0720-048X(02)00303-0
- 8. Qin Y, Tang C, Hu Q, et al. Quantitative assessment of restriction spectrum MR imaging for the diagnosis of breast cancer and association with prognostic factors. *J Magn Reson Imaging*. 2023;57(6):1832–1841. doi:10.1002/jmri.28468
- 9. Wang C, Wang G, Zhang Y, et al. Differentiation of benign and malignant breast lesions using diffusion-weighted imaging with a fractional-order calculus model. Eur J Radiol. 2023;159:110646. doi:10.1016/j.ejrad.2022.110646
- 10. Chen J, Liu D, Guo Y, et al. Preoperative identification of cytokeratin 19 status of hepatocellular carcinoma based on diffusion kurtosis imaging. *Abdom Radiol.* 2023;48(2):579–589. doi:10.1007/s00261-022-03736-6
- 11. Guo Y, Chen J, Zhang Y, et al. Differentiating cytokeratin 19 expression of hepatocellular carcinoma by using multi-b-value diffusion-weighted MR imaging with mono-exponential, stretched exponential, intravoxel incoherent motion, diffusion kurtosis imaging and fractional order calculus models. Eur J Radiol. 2022;150:110237. doi:10.1016/j.ejrad.2022.110237
- 12. Geng Z, Zhang Y, Yin S, et al. Preoperatively grading rectal cancer with the combination of intravoxel incoherent motions imaging and diffusion kurtosis imaging. Contrast Media Mol Imaging. 2020;2020:1–11. doi:10.1155/2020/2164509
- 13. Shi G, Han X, Wang Q, et al. Evaluation of multiple prognostic factors of hepatocellular carcinoma with intra-voxel incoherent motions imaging by extracting the histogram metrics. *Cancer Manag Res.* 2020; Volume 12:6019–6031. doi:10.2147/CMAR.S262973
- 14. Zhang Y, Yang C, Sheng R, Dai Y, Zeng M. Preoperatively identify the microvascular invasion of hepatocellular carcinoma with the restricted spectrum imaging. *Acad Radiol*. 2023;30(Suppl 1):S30–S39. doi:10.1016/j.acra.2023.06.010
- 15. Zhang Y, Yang C, Liang L, et al. Preliminary experience of 5.0 T higher field abdominal diffusion-weighted MRI: agreement of apparent diffusion coefficient with 3.0 T imaging. *J Magn Reson Imaging*. 2022;56(4):1009–1017. doi:10.1002/jmri.28097
- 16. Sheng R, Zhang Y, Sun W, et al. Staging chronic hepatitis B related liver fibrosis with a fractional order calculus diffusion model. *Acad Radiol*. 2022;29(7):951–963. doi:10.1016/j.acra.2021.07.005
- 17. Xiong Z, Geng Z, Lian S, et al. Discriminating rectal cancer grades using restriction spectrum imaging. *Abdom Radiol.* 2022;47(6):2014–2022. doi:10.1007/s00261-022-03500-w
- 18. Le Bihan D, Breton E, Lallemand D, Grenier P, Cabanis E, Laval-Jeantet M. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. *Radiology*. 1986;161(2):401–407. doi:10.1148/radiology.161.2.3763909
- Kuai Z-X, Liu W-Y, Zhu Y-M. Effect of multiple perfusion components on pseudo-diffusion coefficient in intravoxel incoherent motion imaging. *Phys Med Biol.* 2017;62(21):8197. doi:10.1088/1361-6560/aa8d0c
- 20. Cercueil J-P, Petit J-M, Nougaret S, et al. Intravoxel incoherent motion diffusion-weighted imaging in the liver: comparison of mono-, bi-and tri-exponential modelling at 3.0-T. *Eur Radiol.* 2015;25(6):1541–1550. doi:10.1007/s00330-014-3554-6
- 21. Cao M, Wang X, Liu F, Xue K, Dai Y, Zhou Y. A three-component multi-b-value diffusion-weighted imaging might be a useful biomarker for detecting microstructural features in gliomas with differences in malignancy and IDH-1 mutation status. *Eur Radiol*. 2023;33(4):2871–2880. doi:10.1007/s00330-022-09212-5
- 22. Li H, Zhang J, Zheng Z, et al. Preoperative histogram analysis of intravoxel incoherent motion (IVIM) for predicting microvascular invasion in patients with single hepatocellular carcinoma. Eur J Radiol. 2018;105:65–71. doi:10.1016/j.ejrad.2018.05.032
- 23. Wang F, Yan CY, Wang CH, Yang Y, Zhang D. The roles of diffusion kurtosis imaging and intravoxel incoherent motion diffusion-weighted imaging parameters in preoperative evaluation of pathological grades and microvascular invasion in hepatocellular carcinoma. Front Oncol. 2022;12:884854. doi:10.3389/fonc.2022.884854
- 24. Surov A, Pech M, Omari J, et al. Diffusion-weighted imaging reflects tumor grading and microvascular invasion in hepatocellular carcinoma. *Liver Cancer*. 2021;10(1):10–24. doi:10.1159/000511384
- 25. Bradley J, Ju M, Robinson GS. Combination therapy for the treatment of ocular neovascularization. *Angiogenesis*. 2007;10(2):141–148. doi:10.1007/s10456-007-9069-x
- Wei Y, Huang Z, Tang H, et al. IVIM improves preoperative assessment of microvascular invasion in HCC. Eur Radiol. 2019;29(10):5403–5414. doi:10.1007/s00330-019-06088-w
- 27. Zhao W, Liu H, et al. Preoperative prediction of microvascular invasion of hepatocellular carcinoma with IVIM diffusion-weighted MR imaging and Gd-EOB-DTPA-enhanced MR imaging. PLoS One. 2018;13(5):e0197488. doi:10.1371/journal.pone.0197488
- 28. Chevallier O, Zhou N, Cercueil JP, He J, Loffroy R, Wáng YXJ. Comparison of tri-exponential decay versus bi-exponential decay and full fitting versus segmented fitting for modeling liver intravoxel incoherent motion diffusion MRI. NMR Biomed. 2019;32(11):e4155. doi:10.1002/nbm.4155
- 29. Chevallier O, Wáng YXJ, Guillen K, Pellegrinelli J, Cercueil JP, Loffroy R. Evidence of tri-exponential decay for liver intravoxel incoherent motion MRI: a review of published results and limitations. *Diagnostics*. 2021;11(2):379. doi:10.3390/diagnostics11020379
- 30. Riexinger AJ, Martin J, Rauh S, et al. On the field strength dependence of bi- and triexponential Intravoxel Incoherent Motion (IVIM) parameters in the liver. *J Magn Reson Imaging*. 2019;50(6):1883–1892. doi:10.1002/jmri.26730
- 31. Riexinger A, Martin J, Wetscherek A, et al. An optimized b-value distribution for triexponential intravoxel incoherent motion (IVIM) in the liver. Magn Reson Med. 2021;85(4):2095–2108. doi:10.1002/mrm.28582

Journal of Hepatocellular Carcinoma

Dovepress

Publish your work in this journal

The Journal of Hepatocellular Carcinoma is an international, peer-reviewed, open access journal that offers a platform for the dissemination and study of clinical, translational and basic research findings in this rapidly developing field. Development in areas including, but not limited to, epidemiology, vaccination, hepatitis therapy, pathology and molecular tumor classification and prognostication are all considered for publication. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit https://www.dovepress.com/testimonials.php to read real quotes from published authors.

 $\textbf{Submit your manuscript here:} \ \texttt{https://www.dovepress.com/journal-of-hepatocellular-carcinoma-journal-of-hepatocellular-of-hepatocellular-carcinoma-journal-of-hepatocellular-of-hepatocellular-of-hepatocellular-of-hepatocellular-of-hepatocel$



